VEDBAEK, Denmark, Aug. 26, 2009 (GLOBE NEWSWIRE) -- Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced 32% growth in revenue in the first six months of 2009 compared to the same period last year. Organic growth in Exiqon Life Sciences’ research product sales was 21% on the year-earlier period. Exiqon’s full-year revenue guidance is reduced DKK 10 million attributable to Exiqon Diagnostics and now based on an average USD/DKK exchange rate of 5.25 but otherwise maintained including a net loss for the year 2009 at the upper end of the interval DKK 115-130 million including costs of current incentive programs, including warrants, expensed in the amount of DKK 5 million.
